DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: Community Center
Online support, community stories, financial assistance
Co-Pay Relief Brochure
PAF’s Co-Pay Relief Program helps eligible insured individuals by offering financial assistance for co-payment, co-insurance, and deductible expenses related to pharmaceutical treatments and/or medications prescriptions relative to their diagnosis. This brochure provides eligibility criteria, the application process, and contact information for the program.
Related Content
-
videos & visualsISA 2020 | Genetic Signatures & Hereditary ATTR Amyloidosishttps://www.youtube.com/watch?v=ToTGG-zb...
-
people & placesUniversity of Colorado Cardiac Amyloidosis ProgramThe University of Colorado Cardiac Amylo...
-
educationTroubleshooting Advice for Patients Taking Drugs for AL AmyloidosisAL amyloidosis is treated with the same ...
-
people & placesVan Selby, MDDr. Van Selby is a cardiologist who spec...
-
educationCaregiver Tips: Taking Care of YourselfIn some cases, caring for a loved one wi...
-
educationNew and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac AmyloidosisSystemic amyloidoses are rare and protei...
-
news & meetingsUK Approves Phase 1 Trial of Potential Gene Editing Therapy, NTLA-2001The treatment uses CRISPR/Cas9 editing t...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.